Galapagos NV: business update: http://t.co/6w1jppWE
posted 4 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Today Multiplicom and IFFMEDIC announced that IFFMEDIC will act as Multiplicom's agent for the marketing and sales of its molecular diagnostic kits in Central Europe. This agreement is in line with Multiplicom’s strategy to improve access to innovative molecular genetic tests as well as providing expert technical support to medical genetics labs. read more
Almirall, S.A. (ALM.MC) announced today that has formed a research alliance with BioFocus, an affiliate from Galapagos NV (Euronext: GLPG). read more
JSR Corporation (Head Office: Minato-Ku, Tokyo, President: Mitsunobu Koshiba) and BIA Separations (Head Office: Villach, Managing Director and CEO: Aleš Štrancar) announced that they have entered a Strategic partnership which includes a minor equity position by JSR on November 14th 2011. read more
Panama Green Fuels, a company with ambitions to develop green fuel projects in Panama in close collaboration with the Panama government, has agreed to become a member of the Jatropha curcas knowledge platforms of QUINVITA. Both parties maintained an option to develop their relationship for Panama based development of Jatropha plantations on a mutually exclusive basis. read more
The ECOWAS Regional Centre for Renewable Energy and Energy Efficiency (ECREEE), the United Nations Industrial Development Organization (UNIDO), the International Industrial Biotechnology Network (IIBN) and QUINVITA, a global industrial crop technology and knowledge provider for Jatropha, have launched a major strategic study on the potential for sustainable production of novel bio‐energy crops in the ECOWAS region. read more
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has entered into an agreement with Celldex Therapeutics, Inc. (NASDAQ: CLDX). MDxHealth’s epigenetic MGMT test will be used during recruitment of a randomized, double-blind Phase III global clinical study of Celldex’s immunotherapeutic vaccine, rindopepimut, in newly diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer. The study has begun screening patients. Financial terms of the deal were not disclosed. read more
FUGEIA NV kondigt vandaag aan dat het een samenwerkingsakkoord heeft afgesloten met NESTLE voor het ontwikkelen van voedingsmiddelen die Brana Vita[TM]bevatten. read more
Today the recently founded company ADx NeuroSciences NV entered into a license agreement with K.U.Leuven, the academic founder of ADx NeuroSciences. The license agreement grants ADx NeuroSciences exclusive worldwide rights to further develop and commercialise certain antibodies which selectively bind phosphorylated Tau aggregates. ADx NeuroSciences is a new biotech company that focuses on the development of novel (bio)markers for use in the diagnosis of dementia, such as Alzheimer’s, Parkinson’s and other neurodegenerative diseases. read more
